Pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) reduced outpatient antimicrobial purchases in a cluster randomised trial by Palmu, A.A. et al.
 Palmu AA, Jokinen J, Nieminen H, et al: Effect of PHiD-CV10 against antimicrobial purchases 
 
First published in The Lancet Infectious Diseases 2013 Nov 26 dx.doi.org/10.1016/S1473-3099(13)70338-4 
 
This manuscript has been first published at The Lancet Infectious Diseases and is available at  
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2813%2970338-4/abstract 
Citation: Palmu AA, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, Borys D, Lommel P, 
Traskine M, Moreira M, Schuerman L, Kilpi TM. Effect of pneumococcal Haemophilus influenzae protein D conjugate 
vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3–4 trial. The 
Lancet Infectious Diseases, Early Online Publication, 26 November 2013 doi:10.1016/S1473-3099(13)70338-4 
 
 
 
 
Pneumococcal Haemophilus Influenzae Protein D Conjugate Vaccine (PHiD-CV10) reduced 
Outpatient Antimicrobial Purchases in a Cluster Randomised Trial 
 
A.A. Palmu
1* 
MD, J. Jokinen
2
 PhD, H. Nieminen
1
 MD, H. Rinta-Kokko
2 
MSc, E. Ruokokoski
2
 
MSc, T. Puumalainen
5
 MD, D. Borys
3
 MD, P. Lommel
3
 MSc, M. Traskine
3 
MSc, M. Moreira
3 
MD, 
L. Schuerman
3
 MD, T.M. Kilpi
2
 MD, Prof. 
 
1
Department of Vaccination and Immune Protection, National Institute for Health and Welfare, 
FinnMedi I, Biokatu 6, FI-33520 Tampere, Finland 
2
Department of Vaccination and Immune Protection, National Institute for Health and Welfare, P.O. 
Box 30, FI-00271 Helsinki, Finland,  
3
Global Vaccine Development, GlaxoSmithKline Vaccines, Parc de la Noire Epine, 20, Avenue 
Fleming, 1300 Wavre, Belgium 
4
Department of Infectious Diseases Surveillance and Control, National Institute for Health and 
Welfare, P.O. Box 30, FI-00271 Helsinki, Finland,  
5
GlaxoSmithKline Vaccines, Piispansilta 9A, FI-00231, Espoo, Finland (Current affiliation: 
Ministry for Social Affairs and Health, Meritullinkatu 8, FI-00023, Government, Helsinki, Finland) 
 
*Corresponding author: 
Arto A. Palmu, MD, PhD 
National Institute for Health and Welfare (THL) 
Finn-Medi I, Biokatu 6, 33520 Tampere, Finland 
Tel. +358 29 524 7910, arto.palmu@thl.fi 
Fax. +358 32532 390  
 
 
Words in the abstract: 395 
 
Words in the text: 3249 
 
 Palmu AA, Jokinen J, Nieminen H, et al: Effect of PHiD-CV10 against antimicrobial purchases 
 
First published in The Lancet Infectious Diseases 2013 Nov 26 dx.doi.org/10.1016/S1473-3099(13)70338-4 
 
Background 
Antimicrobials are frequently prescribed to children for respiratory tract infections including otitis, 
tonsillitis, sinusitis and pneumonia. We have evaluated the impact of the 10-valent PHiD-CV 
(GlaxoSmithKline Vaccines) on antimicrobial purchases. 
Methods 
In this nationwide phase III/IV cluster-randomised, double-blind trial, children <19 months received 
PHiD-CV10 in two thirds of clusters (N=52) or hepatitis B or A vaccine as control in 26 clusters 
according to 3+1 or 2+1 schedules (infants <7 months) or catch-up schedules (children 7-18 months 
of age). The main objective for the antimicrobial treatment outcome was to assess vaccine 
effectiveness (VE) against outpatient prescriptions of antimicrobials recommended by the national 
treatment guidelines for acute otitis media in Finland (amoxicillin with and without enzyme 
inhibitor, phenoxymethylpenicillin, cefuroxime, cefaclor, sulfadiazine and trimethoprim, 
clarithromycin, azithromycin) in children who received at least one dose of study vaccine before 
seven months of age. Blinded follow-up lasted from the date of first vaccination (from February 
2009 through October 2010) to December 31, 2011. Outcome data i.e. all purchased antimicrobial 
prescriptions, were collected through the benefits register of the Social Insurance Institution of 
Finland. This and the nested acute otitis media trial are registered at ClinicalTrials.gov: 
NCT00861380;NCT00839254. 
Results 
Over 47000 children were enrolled. In 30527 infants <7 months of age at enrolment, 98436 
outpatient antimicrobial purchases were reported with incidence of 1·69 per person-year in the 
control clusters. Analysis of the main objective included 91% of all antimicrobial purchases 
meaning 31982 purchases in the 26 control and 57964 purchases in the 52 PHiD-CV10 clusters. 
The VE was 8% (95% CI 1 to 14%) and the incidence rate difference 0·12 per person-year 
corresponding to the number needed to vaccinate (NNV) of 5 (95% CI 3 to 67) to prevent one 
purchase during the two-year follow-up for combined PHiD-CV10 3+1 and 2+1 infant schedules. 
The VEs were identical for the two infant schedules. In the catch-up schedules, the VE was 3% (95% 
CI; -4 to 10%). 
Conclusions 
We showed that the PHiD-CV10 vaccine reduced the considerable load of outpatient antimicrobial 
purchases in children. Despite low relative rate reductions the absolute rate reductions were 
substantial due to high incidence of the outcome. This would translate into >12000 fewer 
antimicrobial purchases per year in children under 24 months of age in Finland with a birth cohort 
of 60000 children.  
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Panel: Research in context 
 
 
Systematic review 
We searched PubMed and Cochrane Library for reports published in English before July 4, 2013, 
with the following search terms in any fields: “efficacy” or “effectiveness” and “clinical trial” or 
“controlled” and “conjugate vaccine” and “antimicrob* OR antibiot*”. One randomised clinical 
trial with the seven-valent pneumococcal conjugate vaccine (PCV7) administered to infants was 
identified.
17
 Another randomised trial with nine-valent conjugate vaccine given to children 12 to 35 
months of age in day care centres was identified.
18
 No randomised clinical trial data were published 
with the 2+1 infant schedule. One observational prospective cohort study was identified with PCV7 
infant 2+1 schedule in infants.
19
 No clinical trial data were available for the ten or 13-valent PCVs. 
 
Interpretation 
Our study is the first double-blind, randomised controlled trial to document the effectiveness of the 
10-valent pneumococcal conjugate vaccine against antimicrobial use and the first randomized trial 
to show the effectiveness of an infant 2+1 schedule. The vaccine effectiveness estimates of both 
3+1 and 2+1 schedules in the current trial are low, yet slightly higher compared to that reported for 
the 3+1 schedule of the seven-valent pneumococcal conjugate vaccine.
 17
 The low relative vaccine 
effectiveness estimates translate into considerable absolute public health impact due to the high 
incidence of antimicrobial use in children.  
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INTRODUCTION 
 
Antimicrobials are frequently prescribed to treat mucosal respiratory infections in children. High 
incidence of respiratory infections coupled with difficult clinical and aetiological diagnosis, 
especially in determining whether bacterial or viral, as well as parental expectations for active 
treatment have led to significant overuse of antimicrobials. Although encouraging decreasing trends 
have been recently reported,
1,2
 the overuse of antimicrobials remains a public health challenge. 
While most of the mucosal respiratory infections are viral, Streptococcus pneumoniae and 
Haemophilus influenzae are major pathogens in acute otitis media (AOM) in children,
3-5
 and AOM 
is the most common indication for antimicrobial treatment in children in high income countries.
2,6,7
 
 
In clinical trials, pneumococcal conjugate vaccines (PCV) have been shown to reduce vaccine 
serotype-specific AOM by roughly 60%.
5,8,9
 However, the impact on overall AOM has been 
considerably lower, varying from 0 to 34%, due to a variety of pathogens causing the disease and 
also due to replacement disease by pneumococcal non-vaccine serotypes and by other pathogens. In 
observational studies reductions of 19% on average have been observed in otitis media diagnoses 
after the implementation of national vaccination programmes using the first-licensed seven-valent 
PCV (PCV7; Prevenar/Prevnar™, Pfizer, Philadelphia, PA, USA).10  
 
We have earlier reported the effectiveness of the ten-valent pneumococcal conjugate vaccine PHiD-
CV10 (Synflorix™, GlaxoSmithKline Vaccines, Rixensart, Belgium) against invasive 
pneumococcal disease in a cluster randomised clinical trial setting.
11
 We have now evaluated its 
impact on outpatient antimicrobial purchases. 
 
 
 
 
 
 
 
 
 Palmu AA, Jokinen J, Nieminen H, et al: Effect of PHiD-CV10 against antimicrobial purchases 
 
First published in The Lancet Infectious Diseases 2013 Nov 26 dx.doi.org/10.1016/S1473-3099(13)70338-4 
 
METHODS  
 
Trial design and participants 
The Finnish Invasive Pneumococcal disease (FinIP) vaccine trial was designed as a phase III/IV 
double-blind cluster-randomised, controlled field trial. The detailed trial design has been presented 
earlier.
11
  
 
Trial enrolment and vaccinations were performed in collaborating Finnish health care centres (HCC) 
and their local well-baby clinics (WBC, N=651) by the nurses (N>2200) who are responsible for 
routine health follow-up and immunisations of children. A parallel immunogenicity, carriage, and 
AOM trial conducted by the Tampere University Vaccine Research Centre (TAUVRC) used the 
same cluster-randomised design contributing to the results.
12
 TAUVRC enrolled subjects at 15 
dedicated study clinics.  
 
The enrolment started in February 2009 and ended in fall 2010 when PCV was introduced in the 
Finnish National Vaccination Programme for children born on June 1, 2010 or later. A child was 
eligible for enrolment if he/she was six weeks to 18 months of age, had not received and was not 
anticipated to receive any of the study vaccines during the study follow-up, nor had any study 
vaccine-specific or general contraindications to immunisations.  
 
Cluster randomisation and masking  
The areas of the participating HCCs were divided geographically into 72 clusters using 
administrative boundaries (WBC/HCC/municipality) and the birth cohort size. Municipalities 
(N=11) covered exclusively by TAUVRC were split into six additional clusters. The treatment was 
allocated to the 78 clusters using two infant schedules (3+1 or 2+1) and a randomisation ratio of 
2:2:1:1 (PHiD-CV10-3+1:PHiD-CV10-2+1:Control-3+1:Control-2+1). Treatment allocation was 
stratified according to the size of the birth cohort (below/above average), TAUVRC trial enrolment 
(50 of 78 clusters), and urbanity (24 urban and 54 rural clusters). In each cluster and each WBC, all 
enrolled children received the same blinded study vaccine; either PHiD-CV10 or control. The 
details of the randomisation and masking were described earlier.
 11
 
 
Procedures 
The pneumococcal study vaccine included 1 µg of each capsular polysaccharide (PS) for serotypes 
1, 5, 6B, 7F, 9V, 14 and 23F, and 3 µg for serotype 4 each individually conjugated to protein D of 
nontypeable Haemophilus influenzae, and 3 µg of capsular polysaccharide of serotypes 18C and 
19F conjugated to tetanus and diphtheria toxoids, respectively.  
Hepatitis B virus (HBV) vaccine (Engerix B™ 10 µg/0·5 ml) was used as a control vaccine for 
children enrolled before 12 months of age and hepatitis A virus (HAV) vaccine (Havrix™ 720 
Junior) for children enrolled at or after the age of 12 months. The study vaccines were 
manufactured by GlaxoSmithKline Vaccines. 
 
The infant cohort included children enrolled under seven months of age who received either three 
(minimum 4-week intervals) or two (minimum 8-week interval) primary vaccine doses and a 
subsequent booster dose at least four months after the last primary dose, but not earlier than 11 
months of age (infant 3+1 and 2+1 cohorts, respectively). Children enrolled from 7 through 11 
months of age were administered two doses at least four weeks apart followed by a booster dose at 
least four months after the second primary dose (catch-up cohort 7 to 11 months at enrolment). 
Children enrolled from 12 through 18 months of age received two doses at least 6 months apart 
(catch-up cohort 12 to 18 months at enrolment). The study vaccinations were mostly given 
concomitantly with the vaccines of the national vaccination programme. 
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Data on the outpatient antimicrobial purchases were collected through the administrative benefits 
register of the Social Insurance Institution of Finland. All permanent residents in Finland are 
covered by the Finnish National Health Insurance and are eligible for reimbursements for costs of 
reimbursable prescribed medicines, including all antimicrobials for treatment or prevention of 
infections. Pharmacies submit the reimbursement claims of purchased prescriptions for medicines 
automatically online to the Social Insurance Institution of Finland. Antimicrobial drugs are not 
available in Finland without a physician’s prescription. The register data include the ATC code and 
generic name of the drug, the quantity in absolute terms and defined daily doses (DDD), 
pharmaceutical form and concentration, date and costs of the drug purchased, and the identification 
of the subject using the Finnish personal identity code. The actual indication for which the 
antimicrobial was prescribed is not systematically recorded in the register. However, in part of the 
prescriptions the indication could be extracted from the physician’s free text for prescription 
including dosing and other instructions intended for the patient. 
Data on hospital antimicrobial consumption are not available in this register, and were thus not 
considered. In 2009 to 2012, 12% of all systemic antimicrobials were sold to hospitals and 88% for 
outpatient use through pharmacies (www.fimea.fi).  
 
Our main objective was to assess the vaccine effectiveness (VE) against outpatient purchases of 
antimicrobials recommended for treatment of AOM in the national guideline in Finland.13 Here, 
these are defined as antimicrobials recommended for AOM and include amoxicillin without (ATC-
code J01CA04) and with enzyme inhibitor clavulanic acid (J01CR02), phenoxymethylpenicillin 
(J01CE02), cefuroxime (J01DC02), cefaclor (J01DC04), sulfadiazine and trimethoprim (J01EE02), 
clarithromycin (J01FA09), and azithromycin (J01FA10).  
 
Safety follow-up has been reported elsewhere.
11,12
 
 
Statistical analysis 
The primary objective for the antimicrobial treatment outcome was to assess VE against outpatient 
purchases of antimicrobials recommended for AOM in children who received at least one dose of 
PHiD-CV10 before seven months of age either in 3+1 or 2+1 schedule. The sample size for the trial 
was based on the primary objective of the trial, i.e. VE against the invasive pneumococcal disease.
11
 
 
For statistical analyses overall and ATC-code-specific antimicrobial purchases including all (or 
ATC-code-specific) purchases on a given day and the successive day were combined and regarded 
as one purchase. Intention-to-treat (ITT) follow-up for each subject started at the date of the first 
vaccination and ended on December 31, 2011. Incidences were calculated as arithmetic mean of 
cluster-specific incidences and also as number of cases divided by the follow-up in PHiD-CV10 and 
Control groups for the main results. 
To account for between-cluster variability in the incidence of antimicrobial prescriptions, negative 
binomial model was used for the analysis of the effectiveness.
14
 Frequencies of antimicrobial 
prescriptions were grouped by cluster and the cluster-specific person-years were used as weights in 
the analysis. When estimating the effectiveness by schedule, treatment variable was used in the 
model as three-level factor (PHiD-CV10-3+1; PHiD-CV10-2+1; control). Factors used for stratified 
randomisation were included in the model as explanatory variables. Profile likelihood method was 
used to estimate the 95% CIs for the treatment parameter. VE was calculated as 1 minus rate ratio.  
 
Incidence rate difference was calculated as the difference of incidence rate estimates in the PHiD-
CV10 and control groups using negative binomial model. Confidence interval (CI) was calculated 
using the delta method.  
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To investigate the effectiveness on recurrent antimicrobial treatment, prescriptions for each subject 
were ranked according to the sequence of prescription (as first, second, third, etc). Marginal Cox 
regression analysis
15
 was used to estimate effectiveness for each ranked endpoint: for example, 
comparing the incidence of having seventh prescription between the control and PHiD-CV10 
groups. For each ranked endpoint analysis, factors used for stratified randomisation were included 
as explanatory variables and the overdispersion due to cluster-randomised design was accounted for 
by using the sandwich variance estimator.
16
 
 
Due to wide variation detected in the incidence of antimicrobial purchases in the trial clusters, we 
collected historical aggregate data for the birth cohort of 2006 (i.e. cohort not eligible for the trial 
participation) from birth up to 24 months of age. Incidence of purchases by cluster in those born in 
2006 was used as an additional explanatory variable in explorative post hoc analyses to adjust the 
VE analyses for the background variation.  
Statistical analyses were performed with R version 3.0.1 and SAS software (version 9.22; SAS
®
).  
 
The study protocols were approved by the relevant ethical review boards and competent authorities 
before trial start. The full protocol is available at www.finip.fi. This trial and nested AOM trial are 
registered at ClinicalTrials.gov, NCT00861380 and NCT00839254. 
 
Role of the funding source 
This collaborative study was mainly funded by GlaxoSmithKline Biologicals SA and co-funded by 
the National Institute for Health and Welfare (THL). Both parties were involved in all stages of the 
study planning, conduct, data collection, analyses and manuscript development. All authors had 
access to all the data and accepted responsibility for its validity. All authors agreed on the final 
decision to submit for publication. 
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RESULTS 
 
We enrolled 47366 subjects in the 78 clusters between February 18, 2009 and October 5, 2010 
(Figure 1). 45974 subjects who received correctly assigned vaccine were included in the ITT 
analyses.  
 
The primary vaccination series was completed in 97 to 99% of subjects in the PHiD-CV10 and 
control 3+1 and 2+1 infant cohorts. The mean follow-up was 24 months (range 14-34) for infants 
and 27 months (range 13-34) for subjects in the catch-up groups. The baseline and vaccination data 
have been presented earlier in detail.
11
 
During the blinded ITT follow-up we identified a total of 148536 antimicrobial purchases. In the 
control group, the incidences of antimicrobial purchases ranged from 1·38 to 1·69 per person-year 
in the different age cohorts. Amoxicillin was the most common antimicrobial (39%) followed by 
amoxicillin with enzyme inhibitor (18%), azithromycin (16%), and sulfadiazine and trimethoprim 
(13%). Of all antimicrobial purchases, 91% represented antimicrobials recommended for AOM. 
 
The VE of the PHiD-CV10 against the outpatient purchases of antimicrobials recommended for 
AOM in the infant cohort was 8% (95% CI 1 to 14, table 1). The VE estimates for the 3+1 and 2+1 
schedules were almost identical. Furthermore, the impact of both PHiD-CV10 schedules was 
similar during the follow-up from the first dose: it started after three months and sustained at least 
up to 33 months of age (Figure 2).  
The incidence rate difference of purchases of antimicrobials recommended for AOM was 0·12 per 
person-year (table 1). Thus, the NNV was 5 (95% CI 3 to 67) to prevent one purchase during the 
two-year follow-up. 
 
The effectiveness of the vaccine in the infant cohort varied by the antimicrobial agent purchased 
(table 2). The point estimate was highest for amoxicillin with enzyme inhibitor (VE 16%, 0 to 30) 
and between 1 to 10% for other commonly used antimicrobials. 
 
The indication for which the antimicrobial was prescribed was extractable from the prescription text 
for 52% of all prescriptions. However, the indication data were not evenly available across the 
study clusters (range 28-81%) and thus, these data could not be used for VE assessment. 
Nevertheless, out of the prescriptions with indication available, the most frequent indication was 
otitis media for 84% followed by other respiratory tract infections (10%). Antimicrobial 
prophylaxis was the indication in 2% of the prescriptions. The highest impact of the PHiD-CV10 
was seen outside the summer months with highest incidence compatible with epidemics of 
respiratory infections (Figure 3).  
 
The number of outpatient purchases of antimicrobials recommended for AOM ranged from 0 to 30 
per subject (median 2) during the ITT follow-up. The point estimates for the VE became greater 
with the increasing number of antimicrobial purchases per subject as the outcome. For example, the 
incidence rate of the 7
th
 prescription on an individual was reduced by 16% (2 to 27) in the infant 
PHiD-CV10 groups compared to the control group (Figure 4).  
 
We noted considerable variation in the incidence of antimicrobial purchases between the study 
clusters from 1·16 to 2·14 per person-year in the infant control cohorts (Supplement figure 1). 
Therefore, we analysed pre-trial data on antimicrobial consumption for the 2006 birth cohort up to 
24 months of age in the same clusters. These cluster-specific data highly correlated with the trial 
data (Supplement figure 2). Importantly, we observed no imbalance in the randomised clusters and 
the post hoc adjusted analyses with pre-trial data did not impact our VE estimates although the CIs 
were narrower in the adjusted analyses (Supplement table 1). 
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Estimation of the VE in reducing the total DDD consumed and the costs of the antimicrobial 
purchases resulted in similar VE estimates (Supplement table 2). 
 
For the catch-up cohorts, the VE estimates were lower and not statistically significant (table 1).  
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DISCUSSION 
 
Our nationwide randomised trial showed reduction in outpatient antimicrobial purchases in PHiD-
CV10 vaccinated children. Despite low estimates for relative VE, the absolute reduction was 
considerable due to the extensive load of antimicrobial use in the study population.  
Our analysis also suggests that the vaccine impact is greater in those most susceptible to infections 
as the VE estimates increased with the higher number of purchases per child. The vaccine impact 
started early after the first dose of the vaccine and sustained through to third year of life.  
 
Earlier studies have demonstrated impact of the PCVs on antimicrobial consumption. Reduction of 
5·4% (95% CI 4·0 to 6·7) was reported in the randomised, double-blind Northern California Kaiser 
Permanente (NCKP) trial after the first dose of the PCV7 3+1 schedule.
17
 In another randomised, 
double-blind trial
18
 15% reduction of illness episodes treated with antimicrobials (95% CI 3 to 25) 
in day-care attendees 12 to 35 months of age one month after two or one PCV9 doses was reported. 
A study from Italy
19
 reported a reduction of 11% in the number of antimicrobial courses (95% CI 6 
to 17) in a non-randomised observational prospective cohort study of PCV7 2+1 schedule. However, 
the impact was seen only after the booster dose. In a retrospective study, a reduction of up to 42% 
for AOM diagnosis-related antimicrobial treatment has been reported when comparing time period 
after the vaccine implementation to time period before.
20
 Nearly 30% reduction in overall 
antimicrobial consumption was observed two years after PCV7 vaccination programme 
implementation. However, a subsequent study reported similar reduction already before the PCV7 
programme
2
 but less impact after it. Of the studies evaluating the impact of PCV on the 
antimicrobial purchase rates, the Italian study
19
 reports age-specific incidences that are similar to 
the ones reported in this study. For other studies the incidences in the corresponding age groups are 
even higher than in the current study. 
 
We consider our study data of high validity because of the randomised double-blind prospective 
trial design with concurrent controls. The outcome data were collected from an established 
nationwide register. All pharmacies in Finland are obliged to submit all purchased prescriptions to 
the register to get the state reimbursement for the medicines they have delivered. The benefits 
register of the Social Insurance Institution of Finland has collected data on outpatient antimicrobial 
purchases since 1995. We linked our trial data and the benefits register using the national unique 
Personal Identity Code, which is given to all permanent residents in Finland after birth or 
immigration and which remains unchanged through a person’s lifetime. Thus, we consider our 
detection of purchased antimicrobials for the study subjects close to complete. 
 
The Finnish Current Care Guideline
13 
recommends antimicrobial treatment for definite diagnoses of 
AOM with amoxicillin as the primary choice. We selected purchases of the antimicrobials that are 
recommended for treatment of AOM in Finland as the primary endpoint for our analyses since they 
not only represent episodes of AOM, but also excellently reflect the burden caused by them to both 
the health care system and individuals. These antimicrobials comprised 91% of all antimicrobials 
purchased for outpatients, which is consistent with the several studies indicating that respiratory 
infections and especially AOM were known as the most common indications for antimicrobial 
prescriptions.
2,6,7 
 
 
We were not able to collect data related directly to otitis media diagnosis since the actual indication 
of the antimicrobial treatment was not systematically collected in the register. However, in half of 
the prescriptions the indication was written by the prescribing physician and otitis media was by far 
the most common indication found. Therefore, we feel that most of the reduction in antimicrobial 
use is due to a lower incidence on otitis media in the PHiD-CV10 vaccinated children. Furthermore, 
the incidence of antimicrobial treatment in the current trial was close to the incidence of AOM 
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previously reported in Finland.
8
 However, it is also possible, that the vaccine prevented additionally 
other respiratory infections caused by pathogens preventable by PHiD-CV10.  
 
The specificity of the antimicrobial purchase as an outcome for AOM, and especially pneumococcal 
AOM, may be poor for several reasons. First, the clinical diagnosis of AOM is difficult and 
overdiagnosis may occur. Second, the same antimicrobials are also prescribed for other diseases, 
also those with no pneumococcal aetiology, like tonsillitis and urinary tract infections. However, 
due to the double-blind randomised design the potential bias should be symmetric in the treatment 
groups. Furthermore, the low specificity of the outcome should bias the effectiveness estimates 
towards less effect. Therefore, the VE against true mucosal pneumococcal infections is probably 
considerably higher. 
 
The clinical benefit of the antimicrobial use in the treatment of AOM has been recently confirmed 
in infants and young children.
21,22
 Antimicrobials are commonly recommended in many national 
guidelines
13
 and also routinely prescribed as the primary treatment for AOM.
23 
Despite active 
programs to reduce antimicrobial consumption they will continue serving as the cornerstone 
treatment for AOM, especially in children less than two years of age. 
 
The results of this study should be directly generalizable to high income countries with similar high 
prescription rates for respiratory infections in children as the outcome data were collected from 
routine care during the trial. From public health perspective the reduction of antimicrobial 
consumption is important in terms of reduced treatment costs and prevention of the development of 
antimicrobial resistance. More than 12000 antimicrobial purchases and pharmacy costs alone of 
over 200000 € can be averted yearly in children under 24 months of age in Finland with a birth 
cohort of 60000.  
 
In conclusion, the high burden of antimicrobial consumption combined with observed VE translates 
into an exceptionally high absolute reduction, and a low NNV to prevent one outcome (5 per two-
year follow-up). This compares favourably to the IPD results from the same trial with NNV of more 
than 800 per two-year follow-up to prevent one case of culture-confirmed IPD.
11
 Due to a low 
relative and a high absolute effect, the impact of the vaccine on antimicrobial consumption will be 
more readily seen on population level rather than on individual subjects. However, further reduction 
of antimicrobial consumption should be pursuit, especially by reducing inappropriate prescribing. 
This should be easier during the pneumococcal vaccination era when the most serious etiologic 
agent of secondary bacterial infection can be, at least partially, controlled.  
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Table 1. Outpatient purchases of prescribed antimicrobials and the vaccine effectiveness for the 10-valent PHiD-CV during intention-to-treat follow-up  
  Number of 
purchases 
Follow-up time, 
person-years 
Number of 
purchases per 
person-year  
Number of 
purchases per 
person-year, 
cluster-specific 
averages 
Vaccine 
effectiveness (VE) 
Incidence rate 
difference  
Endpoint definition and vaccinated cohort PHiD-
CV10 
group 
Control 
group 
PHiD-
CV10 
group 
Control 
group 
PHiD-
CV10 
group 
Control 
group 
PHiD-
CV10 
group 
Control 
group 
VE point 
estimate 
(%) 
95% CI Reduction 
per person-
year 
95% CI 
Purchase of any outpatient antimicrobial, 
    3+1 and 2+1 schedule combined from dose 1 
63584 34852 40423 20427 1•57 1•71 1•57 1•69 7 1 to 13 0•12 0•01 to 0•23 
Purchase of antimicrobial recommended for AOM*,  
    3+1 and 2+1 schedule combined from dose 1 
57964 31982 40423 20427 1•43 1•57 1•43 1•55 8 1 to 14 0•12 0•01 to 0•23 
Purchase of antimicrobial recommended for AOM,  
    3+1 schedule from dose 1 
29937 31982 20630 20427 1•45 1•57 1•43 1•55 8 -1 to 15 0•12 -0•01 to 0•24 
Purchase of antimicrobial recommended for AOM,  
    2+1 schedule from dose 1 
28027 31982 19793 20427 1•42 1•57 1•43 1•55 8 0 to 15** 0•12 -0•01 to 0•25 
Purchase of antimicrobial recommended for AOM,  
    Catch-up 7-11 months 
12061 6474 8672 4317 1•39 1•50 1•43 1•46 4 -5 to 12 0•05 -0•07 to 0•17 
Purchase of antimicrobial recommended for AOM,  
    Catch-up 12-18 months 
17435 9097 14804 7156 1•18 1•27 1•20 1•23 3*** -5 to 11 0•04 -0•05 to 0•12 
* antimicrobials recommended for treatment of acute otitis media by the national guideline
13
: amoxicillin with and without enzyme inhibitor, phenoxymethylpenicillin, 
cefuroxime, cefaclor, sulfadiazine and trimethoprim, clarithromycin, azithromycin 
** VE 7.8% [95% CI -0•6 to 15•5] according to analysis done using SAS software (version 9.22; SAS®) 
*** VE 3.5% [95% CI -4•6 to 10•9] according to analysis done using SAS software (version 9.22; SAS®)
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Table 2. Outpatient purchases of different antimicrobial agents and the vaccine effectiveness for the 10-valent PHiD-CV during intention-to-treat follow-up 
in infant 3+1 and 2+1 schedules combined 
 Number of purchases 
Number of purchases  
per person-year,  
cluster-specific averages 
Vaccine effectiveness 
(VE) 
Antimicrobial agent PHiD-CV10 
group, 
N=20327 
subjects 
Control 
group, 
N=10200 
subjects 
PHiD-CV10 
group 
Control 
group 
VE point 
estimate 
(%) 
95% CI 
Amoxicillin J01CA04* 25306 13781 0•622 0•672 8 3 to 13 
Amoxicillin and enzyme inhibitor J01CR02* 10980 6673 0•275 0•324 16 0 to 29 
Azithromycin J01FA10* 10364 5533 0•258 0•267 4 -9 to 16 
Sulfadiazine and trimethoprim J01EE02* 8845 4674 0•215 0•223 4 -13 to 19 
Cefalexin J01DB01 5207 2700 0•131 0•134 3 -9 to 14 
Clarithromycin J01FA09* 1326 715 0•031 0•033 2 -24 to 23 
Phenoxymethylpenicillin J01CE02* 805 395 0•020 0•021 1 -20 to 19 
Cefaclor or cefuroxime J01DC04, J01DC02* 668 377 0•016 0•017 10 -28 to 37 
Trimethoprim J01EA01 525 209 0•012 0•009 -39 -109 to 7 
Others 22 22 0•001 0•001 49 -13 to 77 
* antimicrobials recommended in the national guideline for treatment of AOM in Finland
13
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Figure legends 
 
Figure 1: Trial profile  
 
Figure 2. Incidence of outpatient purchases of antimicrobials recommended for AOM by treatment and age in children enrolled before 7 months of age 
 
Figure 3. Incidence of outpatient purchases of antimicrobials recommended for AOM by calendar month in children enrolled before 7 months of age 
 
Figure 4. Vaccine effectiveness against outpatient purchases of antimicrobials recommended for AOM by purchase episode rank in infants (N total 
20327 in the PHiD-CV10 group and 10200 in the control group)  
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Figure 1: Trial profile  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intention-to-
treat follow-
up 
 
 
 
 
 
 * 3 subjects not randomised nor vaccinated, ** includes one subject withdrawn from the register follow-up during the blinded follow-up 
period
~125 000 Finnish-speaking or Swedish-speaking parents of age-eligible children  
identified in population register contacted by mailed invitation letters 
 ~77000 did not participate  
47 366 children enrolled 
41188 in study 043 (NCT00861380) 
6178 in study 053 (NCT00839254)*  
15878 subjects 
 infants <7 months, N=10275 
 catch-up 7-11 months, N=2169 
 catch-up 12-18 months, N=3434 
 
15368 subjects 
 infants <7 months, N=10426 
 catch-up 7-11 months, N=1761 
 catch-up 12-18 months, N= 3181 
 
8442 subjects 
 infants <7 months, N=5550 
 catch-up 7-11 months, N= 1161 
 catch-up 12-18 months, N= 1731 
 
7675 subjects 
 infants <7 months, N=5259 
 catch-up 7-11 months, N=855 
 catch-up 12-18 months, N= 1561 
 
2 excluded 
 infants <7 months,  
o 2 with no vaccinations 
503 excluded 
 infants <7 months,  
o 371 due to randomisation error 
o 1 with no vaccinations 
 catch-up 7-11 months,  
o 50 due to randomisation error 
 catch-up 12-18 months 
o 81 due to randomisation error 
 
883 excluded 
 infants <7 months,  
o 605 due to randomisation error 
o 4 with no vaccinations 
 catch-up 7-11 months 
o 108 due to randomisation error 
 catch-up 12-18 months,  
o 166 due to randomisation error 
 
1 excluded 
 catch-up 7-11 months,  
o 1 with source documents lost 
 
14865 subjects 
o infants <7 months, N=10054** 
o catch-up 7-11 months, N= 1711 
o catch-up 12-18 months, N= 3100 
 
7559 subjects 
o infants <7 months, N=4941 
o catch-up 7-11 months, 1053 
o catch-up 12-18 months, N=1565 
 
7674 subjects 
 infants <7 months, N= 5259** 
 catch-up 7-11 months, N= 854 
 catch-up 12-18 months, N= 1561 
 
78 randomised clusters (ratio 2:2:1:1) 
PHiD-CV10 3+1 (26 clusters) PHiD-CV10 2+1 (26 clusters) Control 3+1 (13 clusters) Control 2+1 (13 clusters) 
15876 subjects 
 infants <7 months, N=10273 
 catch-up 7-11 months, N=2169 
 catch-up 12-18 months, N=3434 
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Figure 2. Incidence of outpatient purchases of antimicrobials recommended for AOM by treatment and age in children enrolled before 7 
months of age. 
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Figure 3. Incidence of outpatient purchases of antimicrobials recommended for AOM by calendar month in children enrolled before 7 months 
of age 
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Figure 4. Vaccine effectiveness against outpatient purchases of antimicrobials recommended for AOM by purchase episode rank in infants (N 
total 20327 in the PHiD-CV10 group and 10200 in the control group)  
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Supplement table 1. Outpatient purchases of prescribed antimicrobials and the vaccine effectiveness for the 10-valent PHiD-CV during intention-to-treat 
follow-up. Results obtained from explorative post hoc analyses using 2006 birth cohort data to adjust the VE analyses for the background variation 
detected in the study clusters. 
 Number of 
purchases 
Follow-up time, 
person-years 
Number of purchases  
per person-year,  
cluster-specific averages 
Vaccine 
effectiveness (VE) 
Endpoint definition and vaccinated cohort PHiD-CV10 
group 
Control 
group 
PHiD-CV10 
group 
Control 
group 
PHiD-CV10 
group 
Control group VE point 
estimate 
(%) 
95% CI 
Purchase of any outpatient antimicrobial,  
 3+1 and 2+1 schedule combined from dose 1 
63584 34852 40423 20427 1•57 1•69 8 4 to 12 
Purchase of antimicrobial recommended for AOM*,  
 3+1 and 2+1 schedule combined from dose 1 
57964 31982 40423 20427 1•43 1•55 9 4 to 13 
Purchase of antimicrobial recommended for AOM,  
 3+1 schedule from dose 1 
29937 31982 20630 20427 1•43 1•55 7 2 to 12 
Purchase of antimicrobial recommended for AOM,  
 2+1 schedule from dose 1 
28027 31982 19793 20427 1•43 1•55 10 5 to 15 
Purchase of antimicrobial recommended for AOM,  
 Catch-up 7-11 months 
12061 6474 8672 4317 1•43 1•46 4 -3 to 11 
Purchase of antimicrobial recommended for AOM,  
 Catch-up 12-18 months 
17435 9097 14804 7156 1•12 1•23 4 -3 to 10 
* antimicrobials recommended for treatment of acute otitis media by the national guideline (ref) : amoxicillin with and without enzyme inhibitor, 
phenoxymethylpenicillin, cefuroxime, cefaclor, sulfadiazine and trimethoprim, clarithromycin, azithromycin 
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Supplement table 2. Outpatient antimicrobial consumption in DDDs, costs for all purchased doses and the vaccine effectiveness for the 10-valent PHiD-
CV during intention-to-treat follow-up  
 
Defined Daily Doses (DDD),  
per 1000 person-years per day 
Vaccine effectiveness 
(VE) 
Costs of the purchased 
antimicrobials,  
Euros (€) per person year 
Vaccine effectiveness 
(VE) 
Endpoint definition and vaccinated cohort 
PHiD-CV10 
group 
Control group 
VE point 
estimate (%) 
95% CI 
PHiD-CV10 
group 
Control 
group 
VE point 
estimate 
(%) 
95% CI 
Purchase of any outpatient antimicrobial,  
 3+1 and 2+1 schedule combined from dose 1 
13•9 15•0 7 1 to 13 20•2 22•1 8 2 to 15 
Purchase of antimicrobial recommended for AOM*,  
 3+1 and 2+1 schedule combined from dose 1 
12•7 13•8 8 1 to 14 18•3 20•2 9 2 to 16 
Purchase of antimicrobial recommended for AOM,  
 Catch-up 7-11 months 
13•9 14•3 3 -6 to 12 19•2 19•6 3 -7 to 12 
Purchase of antimicrobial recommended for AOM,  
 Catch-up 12-18 months 
12•4 12•7 3 -5 to 11 16•6 17•4 4 -4 to 12 
* outpatient antimicrobials recommended for treatment of acute otitis media by the national guideline (ref) : amoxicillin with and without enzyme inhibitor, phenoxymethylpenicillin, 
cefuroxime, cefaclor, sulfadiazine and trimethoprim, clarithromycin, azithromycin 
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Supplement Figure 1: Distribution of any antimicrobial purchase incidences in the study clusters by vaccine group (N=26 per group) in infants 
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Supplement Figure 2: Scatter plots of incidences of antimicrobial purchases in the FinIP infant cohorts and historical data from 2006 to 2008 by the 
study clusters (N=78). Historical and FinIP cohort incidences are not directly comparable because of different follow-up periods, but the figure shows 
the association between the two, as demonstrated by correlation coefficient. 
 
 
 
 
